newsfilter
← Latest News
Business Wire·

HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection

  • Natera, Inc. was named the Best in Class winner in the Cancer, Screening & Early Detection category at the Digital Health Hub Foundation Digital Health & AI Awards.
  • The recognition was announced live at the 2026 HLTH Conference in Las Vegas.
  • The awards competition received more than 1,300 global submissions, with the Cancer, Screening & Early Detection category debuting for the first time this year.
  • Signatera, Natera's personalized molecular residual disease (MRD) test, is the award-winning product that detects circulating tumor DNA (ctDNA) to signal disease recurrence & therapy response.
  • Signatera is the most widely adopted & extensively validated MRD test, utilized by the majority of U.S. oncologists.
  • CEO Solomon Moshkevich stated the test enables earlier interventions & helps spare patients from unnecessary treatment & side effects.
  • Natera's tests are supported by over 475 peer-reviewed publications & operated through ISO 13485-certified & CAP-accredited laboratories in Austin, San Carlos, & Boulder.
  • The press release includes standard forward-looking statements regarding risks, uncertainties, & potential differences between expectations & actual results.